RPG Life Sciences Limited (RPGLIFE) — Financial Results(3 announcements)

RPG Life Sciences announced audited financial results for the quarter and year ended March 31, 2026, along with a dividend recommendation of Rs.24 per share (300% payout) subject to shareholder approval at the upcoming AGM. The Board also appointed Dr. Pratit Samdani as an Additional Non-Executive Independent Director for five years, effective April 29, 2026, and amended its code of fair disclosure. The filing confirms regulatory compliance and outlines post-results trading window protocols.

RPG Life Sciences announced audited financial results for Q4 and FY2025-26 ending March 31, 2026, recommending a Rs.24 dividend per share (300% of Rs.8 face value) pending shareholder approval at the upcoming AGM. The Board also appointed Dr. Pratit Samdani as an Additional Non-Executive Independent Director for five years, effective April 29, 2026, and amended its code of fair disclosure. The updated code is available online, and the trading window will reopen 48 hours after result declaration per SEBI regulations.

RPG Life Sciences reported FY26 revenue of ₹707.5 crores, up 8.3% YoY, with Q4 FY26 revenue at ₹176.9 crores, up 23.6% YoY, and EBITDA margin of 25.6%. The company recommended a 300% dividend (Rs 24 per share) for FY25-26. Key growth drivers included 18.2% domestic formulation growth, 144.3% API division growth, and 13.7% overall DF growth outperforming the 8.6% market rate.